Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors


This study will test the safety, tolerability, and pharmacokinetics of VP301 in patients with relapsed or refractory multiple myeloma, lymphoma, or solid tumors.

SparkCures ID 1338
Trial Phase Phase 1
Enrollment 2 Patients
Trial Sponsors
  • Virtuoso BINco, Inc.
NCT Identifier


Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria:

  • Histologic diagnosis of a refractory solid tumor, refractory myeloma or lymphoma with measurable or evaluable disease
  • Patients must have progressed following all therapies of known, potential clinical benefit, or for whom treatments of known clinical benefit are contraindicated.
  • Adequate kidney, liver, and hematologic function
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2

Exclusion Criteria:

  • Active brain metastases and history of leptomeningeal metastases.
  • Myeloma patients with plasmacytoma as only measurable disease
  • Non-secretory myeloma
  • Patients with advanced metastatic, symptomatic, visceral spread who are at risk of life-threatening complications
  • Active or chronic, uncontrolled bacterial, viral, or fungal infection(s)
  • Abnormal ECG
  • Has clinically significant cardiovascular disease
  • Additional active malignancy that may confound the assessment of the study endpoints
  • Pregnancy or lactation
  • Known seropositivity for HIV (human immunodeficiency virus) or active hepatitis B or hepatitis C

US Trial Locations

Please visit the page for historical site information.

View Centers